Ribociclib for advanced HR+ HER2- breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have invasive breast cancer that is hormone receptor-positive (ER or PgR positive) and HER2-negative.
- Your cancer must be advanced (Stage IV) or have come back after initial treatment (recurrent or unresectable).
- You must be at least 18 years old and in generally good health (ECOG 0-1).
- You cannot have received any hormone therapy or chemotherapy for metastatic or recurrent disease before.
- You cannot have taken a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib) before.
- You must not have serious organ problems, other active cancers, or allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
This study looks at how well ribociclib works when given with hormone therapy after surgery for certain types of breast cancer. It aims to understand real-world benefits and safety for patients in Russia.
This trial tests whether adding the targeted therapy ribociclib (Kisqali) to radiation after surgery reduces the risk of breast cancer returning in patients with high-risk, hormone-positive breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.